ReBio

Oncology

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

News

Kaken has revealed the data that supported its recent marketing application for serabelisib as a treatment for vascular malformations in Japan.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.